MYO3A

Across TCGA pan-cancer cohorts, MYO3A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MYO3A’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where MYO3A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MYO3A is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

PDAC, LUAD, and CCRCC are the cancer types where MYO3A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO3A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	−1.051	<.001	7	view →
LUAD	Male	II,III,IV	−0.652	<.001	7	view →
CCRCC	Male	II,III,IV	−0.369	<.001	7	view →
COAD	All	All	−0.332	.001	7	view →
LSCC	Male	II,III,IV	−0.775	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MYO3A–PDAC

Open the PDAC breakdown →